FDA Approves Dual-Targeted Therapy for Head and Neck Cancer
(MedPage Today) -- The FDA granted accelerated approval to subcutaneous amivantamab and hyaluronidase (Rybrevant Faspro) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma. The approved...
Lean: Center
Fact-focusedFactuality: Mostly factualCountry: United StatesFunding: CorporateOwner: Independent
Medscape FDA Grants Rybrevant Faspro Accelerated Approval for HNSCC
An overall response rate of 42% secures the first approval in a decade for recurrent or metastatic disease after platinum-based chemotherapy.
Lean: Center Fact-focusedFactuality: Mostly factualCountry: United StatesFunding: CorporateOwner: Independent
Coverage breakdown
Funding
Corporate
Countries
United States
Media ownership
Independent
Avg reliability65
Low-credibility share0%
Fact / opinion2/0
State media0%
More analysis
Truth score: 48 (Limited corroboration)
Propaganda risk: 0
Trending: Low
Sources: 2
Reliability: 65
Bias severity: 0
Risk: 0Sentiment: 50Sensationalism: 4
Amplification: 0